The FDA granted Fast Track designation to CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage for the treatment of patients with solid tumors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
